The $2 Trillion Valuation Debate Skips What Anthropic Knows
Pharmacore secures funding to improve medication regimen reviews in long-term care
New ESW Guide Explains Copilot Studio Agent Pricing and the Controls to Set First
EMH Group modernises resident WiFi across its estate with Purple
TestMu AI Launches New Experience in KaneAI, Turning Recorded Tests into Objectives That Repair Themselves
Global multi-arm Phase 2 clinical trial expected to launch in 2024 SAN FRANCISCO, Sept. 26,…
Global multi-arm Phase 2 clinical trial expected to launch in 2024 SAN FRANCISCO, Sept. 26,…
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or…
PDUFA date of January 26th, 2024 Assigned Priority Review Status at the Request of the…
– Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets…
SAN FRANCISCO–(BUSINESS WIRE)–#AndrewButt—Enable, the leading rebate management platform, announced today its first-ever Rebate Strategist Awards…
Ring to present new data on its Anellogy™ platform The first new class of viral…
Cohort dosing complete in healthy subjects, with the Phase I/II study on track to meet…
Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence…
Expects to announce topline data expected in the November/December timeframe. Enrolled patients had underlying medical…
Initial data suggests 12-month survival is consistent with an increased tail on the maturing survival…
Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at several…
Figure 1. Treatment with pepinemab in combination with KEYTRUDA appears to induce formation of highly…
GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the…
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Management portfolio,…
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 million sBLA for F8…
Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total…